Patents by Inventor Lizhu Lin

Lizhu Lin has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20230053737
    Abstract: A traditional Chinese medicine composition for treating EGFR-TKIs related skin rash and a use thereof, characterized by comprising a therapeutically effective amount of the following components: honeysuckle, dandelion, radix sophorae flavescentis, Kochia scoparia, Dictamnus dasycarpus, tree peony root barks, Cortex Phellodendri, and peppermint. The traditional Chinese medicine composition for treating EGFR-TKIs related skin rash has a certain effect for the treatments of EGFR-TKIs related skin rash and paronychia. The raw materials coordinate with each other, thus can play medicinal effects to a maximum extent, thus significantly improving life quality of patients and prolonging survival period of patients. In addition, the traditional Chinese medicine composition also has advantages of non-toxic side effects and lower treatment cost.
    Type: Application
    Filed: December 18, 2020
    Publication date: February 23, 2023
    Applicants: YANGTZE RIVER PHARMACEUTICAL GROUP GUANGZHOU HAIRUI PHARMACEUTICAL CO., LTD., YANGTZE RIVER PHARMACEUTICAL (GROUP) CO., LTD., YANGTZE RIVER PHARMACEUTICAL GROUP JIANGSU LONGFENGTANG TRADITIONAL CHINESE MEDICINE CO., LTD.
    Inventor: Lizhu LIN
  • Patent number: 11524044
    Abstract: This invention provides a strengthening and tumor eliminating traditional Chinese medicine composition, its preparation method and application, which specifically relate to the technical field of the treatment of intermediate and advanced stage and postoperative malignant tumor, wherein the strengthening and tumor eliminating traditional Chinese medicine composition comprises: 8-30 parts of Radix codonopsis, 5-30 parts of Rhizoma atractylodis Macrocephalae, 5-30 parts of Poria cocos, 5-30 parts of Pseudobulb of Appendiculate cremastra, 5-30 parts of Scutellaria barbata, 5-30 parts of Sarcandra glabra, 3-30 parts of peach kernel, 2-30 parts of Ligustrum lucidum, 5-30 parts of Eclipta and 1-20 parts of licorice. This invention also provides a preparation method of the described strengthening and tumor eliminating traditional Chinese medicine composition.
    Type: Grant
    Filed: January 19, 2021
    Date of Patent: December 13, 2022
    Assignee: The First Afiliated Hospital of Guangzhou University of Chinese Medicine
    Inventors: Lizhu Lin, Hongmei Tang, Jianfeng Gan, Detang Li, Lingling Sun
  • Publication number: 20220152143
    Abstract: This invention provides a strengthening and tumor eliminating traditional Chinese medicine composition, its preparation method and application, which specifically relate to the technical field of the treatment of intermediate and advanced stage and postoperative malignant tumor, wherein the strengthening and tumor eliminating traditional Chinese medicine composition comprises: 8-30 parts of Radix Codonopsis, 5-30 parts of Rhizoma Atractylodis Macrocephalae, 5-30 parts of Poria cocos, 5-30 parts of Pseudobulb of Appendiculate Cremastra, 5-30 parts of Scutellaria barbata, 5-30 parts of Sarcandra glabra, 3-30 parts of peach kernel, 2-30 parts of Ligustrum lucidum, 5-30 parts of Eclipta and 1-20 parts of licorice. This invention also provides a preparation method of the described strengthening and tumor eliminating traditional Chinese medicine composition.
    Type: Application
    Filed: January 19, 2021
    Publication date: May 19, 2022
    Inventors: Lizhu Lin, Hongmei Tang, Jianfeng Gan, Detang Li, Lingling Sun
  • Patent number: 8323909
    Abstract: The present invention relates to a small molecule high-throughput screening assay consisting of detectably labeled cardiac progenitor cells. The invention also describes a method of identifying small molecules from the high-throughput assay affecting cardiogenesis and/or modulating cardiac progenitor cell development. Also described are methods of stimulating maturation of cardiac progenitor cells using a GSK-3? inhibitor.
    Type: Grant
    Filed: April 29, 2010
    Date of Patent: December 4, 2012
    Assignee: The Regents of the University of California
    Inventors: Sylvia Evans, Ju Chen, Lizhu Lin, Ken Chien, Yibing Qyang, Alessandra Moretti, Karl Laugwitz
  • Publication number: 20100261196
    Abstract: The present invention relates to a small molecule high-throughput screening assay consisting of detectably labeled cardiac progenitor cells. The invention also describes a method of identifying small molecules from the high-throughput assay affecting cardiogenesis and/or modulating cardiac progenitor cell development. Also described are methods of stimulating maturation of cardiac progenitor cells using a GSK-3? inhibitor.
    Type: Application
    Filed: April 29, 2010
    Publication date: October 14, 2010
    Applicant: THE REGENTS OF THE UNIVERSITY OF CALIFORNIA
    Inventors: Sylvia Evans, Ju Chen, Lizhu Lin, Ken Chien, Yibing Qyang, Alessandra Moretti, Karl Laugwitz
  • Publication number: 20080108090
    Abstract: The present invention relates to a small molecule high-throughput screening assay consisting of detectably labeled cardiac progenitor cells. The invention also describes a method of identifying small molecules from the high-throughput assay affecting cardiogenesis and/or modulating cardiac progenitor cell development. Also described are methods of stimulating maturation of cardiac progenitor cells using a GSK-3? inhibitor.
    Type: Application
    Filed: May 2, 2007
    Publication date: May 8, 2008
    Applicant: THE REGENTS OF THE UNIVERSITY OF CALIFORNIA
    Inventors: Sylvia Evans, Ju Chen, Lizhu Lin, Ken Chien, Yibing Qyang, Alessandra Moretti, Karl Laugwitz